2100 København Ø
The main objective of my PhD project is to apply population pharmacokinetic/pharmacodynamic (PK/PD) modelling techniques to optimize the drug development of fixed dose combination products. More specifically, the aim is to investigate and propose the optimal way to conduct clinical trials with the aim to establish additivity versus synergy between compounds when a significant delay in the response is present (e.g. with HbA1c and body weight as clinical endpoints in the treatment of diabetes and obesity, respectively). As an additional aim, the optimal clinical trial d signs for drug combinations will be investigated, using quantitative criteria that can quantify the balance between primary efficacy and tolerability when side effects are dose limiting.